

Taltz

Procedural steps taken and scientific information after the authorisation*

*Due to the Agency`s update of its procedure management systems, an additional document, reflecting the historical lifecycle may be available in the 'Assessment history' section. For the complete product lifecycle procedures, you may need to also refer to **EPAR - Procedural steps taken and scientific information after authorisation (archive)**.

Application number	Scope	Opinion/ Notification 1 issued on	Commission Decision Issued ² / amended on	Product Information affected ³	Summary
Variation type IB /	C.II.6 Changes to the labelling or the	21/07/2025		PL	To clarify the recommended injection technique for

¹ Notifications are issued for type I variations and Article 61(3) notifications (unless part of a group including a type II variation or extension application or a worksharing application). Opinions are issued for all other procedures.



² A Commission decision (CD) is issued for procedures that affect the terms of the marketing authorisation (e.g. summary of product characteristics, annex II, labelling, package leaflet). The CD is issued within two months of the opinion for variations falling under the scope of Article 23.1a(a) of Regulation (EU) No. 712/2012, or within one year for other procedures.

³ SmPC (Summary of Product Characteristics), Annex II, Labelling, PL (Package Leaflet).

EMA/VR/0000269322	package leaflet which are not connected with the summary of product characteristics - b)		the 40 mg pre-filled syringe IFU by updating one image and the explanatory text for 2 images, as
			• • • • • • • • • • • • • • • • • • • •
	Other changes - Accepted		well as the text explaining when the injection is
			complete.
	To clarify the recommended injection		
	technique for the 40 mg pre-filled syringe		
	IFU by updating one image and the		
	explanatory text for 2 images, as well as the		
	text explaining when the injection is		
	complete.		